Last checked at 
(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in peanut-allergic patients on Monday.
The firm said its short-course peanut allergy vaccine was being tested in the phase one 'PROTECT' trial.
It said the first-in-human study was focussed on evaluating the safety and tolerability of VLP Peanut in healthy and peanut-allergic adult subjects, while exploring preliminary proof of efficacy.
"Allergy Therapeutics' wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body's immune response by making the peanut allergen resemble an inactive virus," the company explained in its statement.
Reporting by Josh White for Sharecast.com.
